Key result
Echocardiography and multimodality imaging remain essential for diagnosing and managing HCM.
Why the study?
Earlier diagnosis and proper identification of high-risk hypertrophic cardiomyopathy patients may reduce morbidity and mortality by promoting timely treatment, with an expanding role for multimodality imaging.
Multimodality imaging, primarily echocardiography supplemented by CT and MRI, is essential for the diagnosis, risk stratification, and management of hypertrophic cardiomyopathy.
Reinforces imaging centrality in HCM evaluation; leaves open optimal multimodality protocols for risk stratification.
Hypertrophic cardiomyopathy (HCM) is an underdiagnosed genetic heart disease with an estimated prevalence of 0.2-0.5%. Although the prognosis of HCM is relatively good, with an annual general mortality of ~0.7%, some patients have an increased risk of sudden death, or of developing severe heart failure requiring heart transplantation or left ventricular (LV) assist device therapy. Therefore, earlier diagnosis and proper identification of high-risk patients may reduce disease-related morbidity/mortality by promoting timely treatment. Echocardiography is the primary imaging modality for patients with suspected HCM; it plays central roles in differential diagnosis from other causes of LV hypertrophy and in evaluating morphology, hemodynamic disturbances, LV function, and associated valvular disease. Echocardiography is also an essential tool for the continuous clinical management of patients with confirmed HCM. Other imaging modalities, such as cardiac computed tomography (CT) and cardiac magnetic resonance imaging (MRI), can supplement echocardiography in identifying high-risk as well as milder HCM phenotypes. The role of such multimodality imaging has been steadily expanding along with recent advancements in surgical techniques and minimally invasive procedures, and the emergence of novel pharmacotherapies directly targeting pathogenic molecules such as myosin inhibitors. Here we review essential knowledge surrounding HCM with a specific focus on structural and functional abnormalities assessed by imaging modalities, leading to treatment strategies.
No takes yet. Share an insight, caveat, or question.
Kitai et al. (2022) conducted a review in Hypertrophic cardiomyopathy (HCM). Echocardiography and multimodality imaging was evaluated. Echocardiography and multimodality imaging are essential for the diagnosis and management of hypertrophic cardiomyopathy, a genetic heart disease with an estimated prevalence of 0.2-0.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: